TEN-YEAR PIVOTAL DATA REINFORCE THE LONG-TERM DURABILITY OF EDWARDS' RESILIA TISSUE

by | PRNewswire Asia

SINGAPORE, May 4, 2026 /PRNewswire/ — Edwards Lifesciences, the leading global structural heart innovation company, recently announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its...

Meiyume (Group) LTD Achieves EcoVadis Gold Rating for 2026, Reinforcing Commitment to Sustainable Beauty

by | PRNewswire Asia

HONG KONG, May 4, 2026 /PRNewswire/ — Meiyume (Group) LTD has achieved the EcoVadis Gold rating for 2026, with the company being in the 96th percentile globally and among the top-performing companies for sustainability. Meiyume – Ecovadis Gold 2026...

COSRX Ultra-Light Invisible Sunscreen SPF50 PA++++, UK's No.1 Bestseller Sunscreen with CPNP Certification, Solidifies Leadership in Thailand

by | PRNewswire Asia

4.9-Star Rating on Shopee and TikTok Shop Thailand | 16,000+ Verified Reviews Key Highlights Ranked #1 in Sunscreen category on Amazon UK (*April 14, 2026)  A European favorite, certified under EU CPNP – one of the world’s strictest cosmetic standards...

XtalPi -Enabled PharmaEngine PEP08 Achieves Enrollment Milestone, with Second Synthetic Lethality Program Underway

by | PRNewswire Asia

SHENZHEN, China, May 4, 2026 /PRNewswire/ — XtalPi (2228.HK), a leading AI- and robotics-powered innovation platform, today announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO) PEP08, a next-generation PRMT5 inhibitor discovered...

IMDA and Tencent Debut "Beyond the Screen" to Champion Real-World Connection through Digital Play

by | PRNewswire Asia

The launch is marked by the signing of an agreement between IMDA and Tencent to advance healthy digital habits and safe, responsible use of digital technologies among youths, parents, and families. SINGAPORE, May 2, 2026 /PRNewswire/ — The Infocomm Media...

Restore Vision Announces First-in-Human Clinical Interim Results for RV-001, a GPCR-Based Optogenetic Gene Therapy

by | PRNewswire Asia

Phase I/II clinical trial interim results, out to 168 days, from the two RV-001 dosing cohorts with advanced Retinitis Pigmentosa are presented at key May 2026 meetings: Eyecelerator and Retinal Therapeutics Innovation Summit. No dose-limiting toxicities (DLTs) or...